1. Cancer immunotherapy: the beginning of the end of cancer?
2. IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
3. Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Phase III JAVELIN Gastric 300 Study in Patients with Pre-Treated Advanced Gastric Cancerhttps://www.pfizer.com/news/press-release/press-release-detail/merck_kgaa_darmstadt_germany_and_pfizer_provide_update_on_phase_iii_javelin_gastric_300_study_in_patients_with_pre_treated_advanced_gastric_cancer
4. Genentech Provides Update on Phase III Study of TECENTRIQ (Atezolizumab) in People with Previously Treated Advanced Bladder Cancerhttps://www.gene.com/media/press-releases/14665/2017-05-09/genentech-provides-update-on-phase-iii-s
5. Bristol-Myers Squibb Announces Top-Line Results from CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) in Treatment-Naïve Patients with Advanced Non-Small Cell Lung Cancerhttps://news.bms.com/press-release/bristolmyers/bristol-myers-squibb-announces-top-line-results-checkmate-026-phase-3-stu